Genitourinary Cancers

Some patients with metastatic kidney cancer achieving a good response to a combination therapy can safely stop or pause treatment after 2 years.

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

The FDA has granted priority review to belzutifan for advanced pheochromocytoma and paraganglioma.

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

Felix Y. Feng, MD, a radiation oncologist and researcher at UCSF, died of cancer on December 10, 2024, at 48 years old.

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.